Bristol Myers Squibb Company $BMY Holdings Reduced by Viking Fund Management LLC

Viking Fund Management LLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 15.8% during the 3rd quarter, Holdings Channel reports. The fund owned 373,000 shares of the biopharmaceutical company’s stock after selling 70,000 shares during the quarter. Bristol Myers Squibb comprises 1.9% of Viking Fund Management LLC’s portfolio, making the stock its 8th largest holding. Viking Fund Management LLC’s holdings in Bristol Myers Squibb were worth $23,275,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in BMY. BlackRock Inc. raised its stake in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp raised its stake in shares of Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after buying an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Bristol Myers Squibb by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after buying an additional 520,330 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $59.34 on Thursday. The company’s 50 day moving average price is $63.72 and its 200 day moving average price is $60.28. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a market capitalization of $121.22 billion, a PE ratio of 13.07, a PEG ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.70 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Analyst Ratings Changes

BMY has been the topic of several recent research reports. TD Cowen began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. Truist Financial reissued a “buy” rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Rothschild & Co Redburn raised their target price on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Daiwa Securities Group lifted their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $64.88.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress supports long-term growth prospects. Bristol Myers reported favorable Phase 3 data for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including improved progression-free survival. The results could support upcoming regulatory discussions and help diversify the company beyond existing blockbuster drugs. What Could Bristol Myers Squibb Two Phase 3 Wins Change?
• Positive Sentiment: Analyst support and dividend appeal remain positives. Truist Financial maintained its Buy rating, while coverage of Bristol Myers continues to highlight its dividend and ability to replace aging blockbuster medicines. The stock’s relatively low valuation and approximately 38% one-year gain have also attracted investor attention. Truist Maintains Buy Rating
• Neutral Sentiment: Investor attention is elevated, but coverage is mixed. BMY is a trending stock on Zacks, while several analyst roundups describe divided opinions across healthcare stocks. The increased visibility may support trading interest, but it does not represent a fundamental change by itself. Bristol Myers Squibb Trending Stock
• Negative Sentiment: Clinical results included an important caveat. Reports characterized the Phase 3 results for admilparant in idiopathic pulmonary fibrosis as mixed, despite descriptions of clinical benefits and a favorable safety profile. That uncertainty may limit the immediate value investors assign to the respiratory pipeline. BMY Reports Mixed Phase III Trial Results
• Negative Sentiment: Wells Fargo reduced its valuation view. The firm cut its price target from $65 to $60 and kept an Equal Weight rating, signaling limited near-term upside and reinforcing concerns about valuation, execution, and pipeline risks. Wells Fargo Lowers BMY Price Target

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.